Anti-inflammatory mechanism of lonchocarpine in LPS- or poly(I:C)-induced neuroinflammation

Pharmacological Research

Volumn 119, Issue , 2017, Pages 431-442

  Jeong, Yeon Hui ^a   Park, Jin Sun ^a   Kim, Dong Hyun ^b   Kang, Jihee Lee ^a   Kim, Hee Sun ^a  

^a Ewha Womans University School of Medicine   (South Korea)

^b Kyung Hee University   (South Korea)

Author keywords

Lipopolysaccharide; Lonchocarpine; Microglia; Molecular mechanism; Neuroinflammation; Poly(I:C)

Indexed keywords

ABRUS PRECATORIUS EXTRACT; ANTIINFLAMMATORY AGENT; CYTOKINE; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; LIPOPOLYSACCHARIDE; LONCHOCARPINE; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG; BENZOPYRAN DERIVATIVE; CHALCONE DERIVATIVE; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ABRUS PRECATORIUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN; BRAIN CORTEX; BV2 CELL LINE; CELL STIMULATION; CONTROLLED STUDY; DRUG ISOLATION; ENCEPHALITIS; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PLANT ROOT; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; ABRUS; ANIMAL; CELL LINE; CHEMISTRY; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; ISOLATION AND PURIFICATION;

ABRUS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BENZOPYRANS; CELL LINE; CHALCONES; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MICE; MICROGLIA; POLY I-C; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85015368982     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.02.027     Document Type: Article

References (35)

1. [1] Garden, G.A., Moller, T., Microglia biology in health and disease. J. Neuroimmune Pharmacol. 1 (2006), 127–137.
2. [2] Gomez-Nicola, D., Perry, V.H., Microglial dynamics and role in the healthy and diseased brain: a paradigm of functional plasticity. Neuroscientist 21 (2015), 169–184.
3. [3] Cherry, J.D., Olschowka, J.A., O'Banion, M.K., Neuroinflammation and M2 microglia: the good, the bad, and the inflammed. J. Neuroinflammation, 11, 2014, 98.
4. [4] Hanisch, U.K., Kettenmann, H., Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 10 (2007), 1387–1394.
5. [5] Glass, C.K., Saijo, K., Winner, B., Marchetto, M.C., Gage, F.H., Mechanisms underlying inflammation in neurodegeneration. Cell 140 (2010), 918–934.
6. [6] Streit, W.J., Mrak, R.E., Griffin, W.S., Microglia and neuroinflammation: a pathological perspective. J. Neuroinflammation, 1, 2004, 14.
7. [7] Hoogland, I.C.M., Houbolt, C., Westerloo, D.J., Gool, W.A., van de Beek, D., Systemic inflammation and microglial activation: systemic review of animal experiments. J. Neuroinflammation, 12, 2015, 114.
8. [8] Qin, L., Wu, X., Block, M.L., Liu, Y., Breese, G.R., Hong, J.S., Knapp, D.J., Crews, F.T., Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55 (2007), 453–462.
9. [9] Cunningham, C., Campion, S., Teeling, J., Felton, L., Perry, V.H., The sickness behaviour and CNS inflammatory mediator profile induced by systemic challenge of mice with synthetic double-stranded RNA (poly I:C). Brain Behav. Immun. 21 (2007), 490–502.
10. [10] Perry, V.H., Holmes, C., Microglial priming in neurodegenerative disease. Nat. Rev. Neurol. 10 (2014), 217–224.
11. [11] Georgewill, O.A., Georgewill, U.O., Evaluation of the anti-inflammatory activity of extract of Abrus precatorious. East. J. Med. 14 (2009), 23–25.
12. [12] Gul, M.Z., Ahmad, F., Kondapi, A.K., Qureshi, I.A., Ghazi, I.A., Antioxidant and antiproliferative activities of Abrus precatorius leaf extracts – an in vitro study. BMC Complement. Altern. Med., 13, 2013, 53.
13. [13] Premanand, R., Ganesh, T., Neuroprotective effects of Abrus precatorius Linn. aerial extract on hypoxic neurotoxicity induced rats. Int. J. Chem. Pharmaceut. Sci. 1 (2010), 9–15.
14. [14] Fontenele, J.B., Leal, L.K., Felix, F.H., Silveira, E.R., Viana, G.S., Studies on the anti-oedematogenic properties of a fraction rich in lonchocarpin and derricin isolated from Lonchocarpus sericeus. Nat. Prod. Res. 23 (2009), 1677–1688.
15. [15] Lima, N.M., Andrade, J.I., Lima, K.C., dos Santos, F.N., Barison, A., Salome, K.S., Matsuura, T., Nunez, C.V., Chemical profile and biological activities of Deguelia duckeana A.M.G. Azevedo (Fabaceae). Nat. Prod. Res. 27 (2013), 425–432.
16. [16] Reyes-Chilpa, R., Baggio, C.H., Alavez-Solano, D., Estrada-Muniz, E., Kauffman, F.C., Sanchez, R.I., Mesia-Vela, S., Inhibition of gastric H+,K+-ATPase activity by flavonoids, coumarins and xanthones isolated from Mexican medicinal plants. J. Ethnopharmacol. 105 (2006), 167–172.
17. [17] Jeong, Y.H., Park, J.S., Kim, D.H., Kim, H.S., Lonchocarpine increases Nrf2/ARE-mediated antioxidant enzyme expression by modulating AMPK and MAPK signaling in brain astrocytes. Biomol. Ther. 24:6 (2016), 581–588.
18. [18] Bocchini, V., Mazzolla, R., Barluzzi, R., Blasi, E., Sick, P., Kettenmann, H., An immortalized cell line expresses properties of activated microglial cells. J. Neurosci. Res. 31 (1992), 616–621.
19. [19] Lee, E.J., Ko, H.M., Jeong, Y.H., Park, E.M., Kim, H.S., β-Lapachone suppresses neuroinflammation by modulating the expression of cytokines and matrix metalloproteinases in activated microglia. J. Neuroinflammation, 12, 2015, 133.
20. [20] Kawai, T., Akira, S., Signaling to NF-kappaB by Toll-like receptors. Trends Mol. Med. 13 (2007), 460–469.
21. [21] Hayden, M.S., Ghosh, S., Shared principles in NF-kappaB signaling. Cell 132 (2008), 344–362.
22. [22] Johnson, G.L., Lapadat, R., Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298 (2002), 1911–1912.
23. [23] Roux, P.P., Blenis, J., ERK and p38 MAPK-activated protein kinases a family of protein kinases with diverse biological functions. Microbiol. Mol. Biol. Rev. 68 (2004), 320–344.
24. [24] Hsieh, H.L., Yang, C.M., Role of redox signaling in neuroinflammation and neurodegenerative diseases. Biomed. Res. Int., 2013, 2013, 484613.
25. [25] Gao, H.M., Zhou, H., Hong, J.S., NADPH oxidases novel therapeutic targets for neurodegenerative diseases. Trends Pharmacol. Sci. 33 (2012), 295–303.
26. [26] Carty, M., Bowie, A.G., Evaluating the role of Toll-like receptors in diseases of the central nervous system. Biochem. Pharmacol. 8 (2011), 825–837.
27. [27] Barichello, T., Generoso, J.S., Goularte, J.A., Collodel, A., Pitcher, M.R., Simoes, L.R., Quevedo, J., Dal-Pizzol, F., Does infection-induced immune activation contribute to dementia?. Aging Dis. 6 (2015), 342–348.
28. [28] Hanke, M.L., Kielian, T., Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential. Clin. Sci. 121 (2011), 367–387.
29. [29] Lehnardt, S., Massillon, L., Follett, P., Jensen, F.E., Ratan, R., Rosenberg, P.A., Volpe, J.J., Vartanian, T., Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc. Natl. Acad. Sci. U.S.A. 100 (2003), 8514–8519.
30. [30] Kawai, T., Akira, S., TLR signaling. Cell Death Differ. 13 (2006), 816–825.
31. [31] Chen, I.T., Hsu, P.H., Hsu, W.C., Chen, N.J., Tseng, P.H., Polyubiquitination of transforming growth factor beta-activated kinase 1 (TAK1) at lysine 562 residue regulates TLR4-mediated JNK and p38 MAPK activation. Sci. Rep., 5, 2015, 12300.
32. [32] Carpentier, P.A., Duncan, D.S., Miller, S.D., Glial toll-like receptor signaling in central nervous system infection and autoimmunity. Brain Behav. Immun. 22 (2008), 140–147.
33. [33] Kong, X., Thimmulappa, R., Kombairaju, P., Biswal, S., NADPH oxidase-dependent reactive oxygen species mediate amplified TLR4 signaling and sepsis-induced mortality in Nrf2-deficient mice. J. Immunol. 185 (2010), 569–577.
34. [34] Kim, K.C., Gonzales, E.L., Lazaro, M.T., Choi, C.S., Bahn, G.H., Yoo, H.J., Shin, C.Y., Clinical and neurological relevance of current animal models of autism spectrum disorders. Biomol. Ther. 24 (2016), 207–243.
35. [35] Reisinger, S., Khan, D., Kong, E., Berger, A., Pollak, A., Pollak, D.D., The Poly(I:C)-induced maternal immune activation model in preclinical neuropsychiatric drug discovery. Pharmarcol. Ther. 149 (2015), 213–226.